Košík
zboží
(prázdné)
Kontakt
Účet
MEGA VÝHODNÉ
Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg (R)), Brentuximab vedotin (Adcetris (R)), and ado-trastuzumab emtansine (Kadcyla (R)), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).
číst celé
Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg (R)), Brentuximab vedotin (Adcetris (R)), and ado-trastuzumab emtansine (Kadcyla (R)), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).
schovat popis
- Nakladatel: Springer International Publishing AG
- Kód:
- Rok vydání: 2016
- Jazyk: Angličtina
- Vazba: Brožovaná
- Počet stran: 252
- Šířka balení: 15.5 cm
- Výška balení: 23.7 cm
- Hloubka balení: 1.9 cm
- Váha balení: 428 g
Recenze